Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 6/20 | 0.52 |
| ▸ | PGR | P06401 | 5/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14200096 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL29519614 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL13139936 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL17302786 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL13397495 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL12437208 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL8843324 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL12101456 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL11747587 | 0.89 | AR (0.48) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL24711581 | 0.86 | MAPT (0.49) | CYP17A1ARPGRNR3C2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118995644-A | Cytochrome P450BM3 mutant, vector, microorganism and application thereof | 湖北大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118995644-A | Cytochrome P450BM3 mutant, vector, microorganism and application thereof | 湖北大学 | 2024-11-22 | — | — | CN | disclosed |
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| US-11541062-B2 | Methods of treating advanced prostate cancer | CITY OF HOPE (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022257895-A1 | INTERMEDIATE FOR PREPARING FULVESTRANT AND PREPARATION METHOD THEREFOR | 上海弼领生物技术有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-20200188416-A1 | METHODS OF TREATING ADVANCED PROSTATE CANCER | CITY OF HOPE | 2020-06-18 | — | — | US | disclosed |
| US-10603328-B2 | Methods of treating advanced prostate cancer | CITY OF HOPE (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180311261-A1 | METHODS OF TREATING ADVANCED PROSTATE CANCER | CITY OF HOPE | 2018-11-01 | — | — | US | disclosed |
| WO-2017064724-A1 | NOVEL PROCESS AND INTERMEDIATES FOR THE PREPARATION OF HIGH PURITY FULVESTRANT | NATCO PHARMA LTD (IN) | 2017-04-20 | — | — | WO | disclosed |
| EP-2183267-B1 | PROCESS FOR PREPARING 7-ALPHA-[9-(4,4,5,5,5-PENTAFLUOROTHIOPENTYL) NONYL]ESTRA-1,3,5(10)-TRIENE-3,17-BETA-DIOL | IND CHIMICA SRL (IT) | 2014-08-20 | — | — | EP | disclosed |
| EP-0615448-A1 | SEX STEROID ACTIVITY INHIBITORS | ENDORECHERCHE INC. (CA) | 1994-09-21 | — | — | EP | disclosed |
| EP-0595796-A1 | METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES | ENDORECHERCHE INC. (CA) | 1994-05-11 | — | — | EP | disclosed |
| WO-1993010741-A2 | SEX STEROID ACTIVITY INHIBITORS | ENDORECHERCHE INC. (CA) | 1993-06-10 | — | — | WO | disclosed |
| US-5204337-A | Estrogen nucleus derivatives for use in inhibition of sex steroid activity | ENDORECHERCHE INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| EP-0480950-A1 | COMBINATION THERAPY FOR PROPHYLAXIS AND/OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ENDORECHERCHE INC. (CA) | 1992-04-22 | — | — | EP | disclosed |
| WO-1991000731-A1 | COMBINATION THERAPY FOR PROPHYLAXIS AND/OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ENDORECHERCHE INC. (CA) | 1991-01-24 | — | — | WO | disclosed |
| WO-1991000733-A1 | METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES | ENDORECHERCHE INC. (CA) | 1991-01-24 | — | — | WO | disclosed |
| EP-0367576-A2 | Estrogen nucleus derivatives for use in the inhibition of sex steroid activity | ENDORECHERCHE INC. (CA) | 1990-05-09 | — | — | EP | disclosed |
| US-4073899-A | 7A-METHYL-ESTR-5-ENE-3B,17B-DIOL AND 17-ACYL ESTERS | RICHARDSON-MERRELL, INC. (US) | 1978-02-14 | — | — | US | disclosed |
| US-4000273-A | METHOD FOR THE CONTROL OF FERTILITY | RICHARDSON-MERRELL INC. (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | CYP17A1 18/4885AR 7/4885PGR 16/4885 |
| US-20200188416-A1 | METHODS OF TREATING ADVANCED PROSTATE CANCER | KLK3, AR, ACP3 | CYP17A1 12/4885AR 2/4885PGR 104/4885 |
| US-20180311261-A1 | METHODS OF TREATING ADVANCED PROSTATE CANCER | KLK3, AR, ACP3 | CYP17A1 12/4885AR 2/4885PGR 104/4885 |
| US-10603328-B2 | Methods of treating advanced prostate cancer | KLK3, AR, ACP3 | CYP17A1 12/4885AR 2/4885PGR 104/4885 |
| US-11541062-B2 | Methods of treating advanced prostate cancer | KLK3, AR, ACP3 | CYP17A1 12/4885AR 2/4885PGR 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.